1. Home
  2. GNPX vs SAG Comparison

GNPX vs SAG Comparison

Compare GNPX & SAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNPX
  • SAG
  • Stock Information
  • Founded
  • GNPX 2009
  • SAG 1975
  • Country
  • GNPX United States
  • SAG Singapore
  • Employees
  • GNPX N/A
  • SAG N/A
  • Industry
  • GNPX Biotechnology: Pharmaceutical Preparations
  • SAG
  • Sector
  • GNPX Health Care
  • SAG
  • Exchange
  • GNPX Nasdaq
  • SAG NYSE
  • Market Cap
  • GNPX 6.2M
  • SAG 7.1M
  • IPO Year
  • GNPX 2018
  • SAG 2024
  • Fundamental
  • Price
  • GNPX $0.27
  • SAG $1.04
  • Analyst Decision
  • GNPX Strong Buy
  • SAG
  • Analyst Count
  • GNPX 1
  • SAG 0
  • Target Price
  • GNPX $10.00
  • SAG N/A
  • AVG Volume (30 Days)
  • GNPX 7.3M
  • SAG 350.2K
  • Earning Date
  • GNPX 05-13-2025
  • SAG 12-19-2024
  • Dividend Yield
  • GNPX N/A
  • SAG N/A
  • EPS Growth
  • GNPX N/A
  • SAG N/A
  • EPS
  • GNPX N/A
  • SAG 0.21
  • Revenue
  • GNPX N/A
  • SAG $56,387,000.00
  • Revenue This Year
  • GNPX N/A
  • SAG N/A
  • Revenue Next Year
  • GNPX N/A
  • SAG N/A
  • P/E Ratio
  • GNPX N/A
  • SAG $4.90
  • Revenue Growth
  • GNPX N/A
  • SAG N/A
  • 52 Week Low
  • GNPX $0.22
  • SAG $0.47
  • 52 Week High
  • GNPX $4.09
  • SAG $8.27
  • Technical
  • Relative Strength Index (RSI)
  • GNPX 44.92
  • SAG N/A
  • Support Level
  • GNPX $0.23
  • SAG N/A
  • Resistance Level
  • GNPX $0.44
  • SAG N/A
  • Average True Range (ATR)
  • GNPX 0.04
  • SAG 0.00
  • MACD
  • GNPX 0.00
  • SAG 0.00
  • Stochastic Oscillator
  • GNPX 26.65
  • SAG 0.00

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About SAG SAG HOLDINGS LTD

SAG Holdings Ltd engages in the business of distributing automotive and industrial spare parts with operations primarily based in Singapore, and global sales primarily generated from the Middle East and Malaysia. Its business is comprised of On-Highway Business serving the automotive sector and Off-Highway Business primarily servicing the marine, energy, mining, construction, agriculture, and oil and gas sectors. The On-Highway Business Segment supply genuine and aftermarket spare parts to customers through our Autozone retail outlets located in Singapore, as well as Malaysia. The Off-Highway Business Segment supply a wide range of components and spare parts for internal combustion engines with a strong focus on filtration products through Filtec.

Share on Social Networks: